Nanoviricides (NNVC) Non-Current Debt (2013 - 2023)
Nanoviricides (NNVC) posted Non-Current Debt of $1.5 million for Q3 2023, little changed sequentially from $1.5 million in Q2 2023, and up 6192.74% YoY from $23837.0 in Q3 2022.
Nanoviricides (NNVC) Non-Current Debt (2013 - 2023) Analysis & Trends
Nanoviricides has reported Non-Current Debt for 9 years, with the latest figure at $1.5 million in Q3 2023.
- Quarterly Non-Current Debt rose 6192.74% year-over-year to $1.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $1.5 million (up 6192.74% YoY) and the FY2023 annual result came in at $1.5 million, up 1482.48% from the prior year.
- Non-Current Debt steadied at $1.5 million in Q3 2023 per NNVC's latest filing, from $1.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $1.5 million in Q2 2023 and troughed at $15809.0 in Q3 2020.
- A 4-year average of $341505.1 and a median of $95306.0 in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt retreated 0.54% in 2022, then soared 6192.74% in 2023.
- Over 4 years, Non-Current Debt stood at $15809.0 in 2020, then soared by 51.6% to $23967.0 in 2021, then declined by 0.54% to $23837.0 in 2022, then jumped by 6192.74% to $1.5 million in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.5 million, $1.5 million, and $23837.0 for Q3 2023, Q2 2023, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | Nanoviricides | 29.50 Mn | 26.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Sep 30, 2022 | 23,837.00 |
| Jun 30, 2022 | 94,788.00 |
| Mar 31, 2022 | 164,905.00 |
| Sep 30, 2021 | 23,967.00 |
| Jun 30, 2021 | 95,306.00 |
| Mar 31, 2021 | 165,806.00 |
| Sep 30, 2020 | 15,809.00 |
| Jun 30, 2020 | 62,843.00 |
| Mar 31, 2020 | 109,295.00 |
| Jun 30, 2017 | 3.96 Mn |
| Mar 31, 2017 | 3.73 Mn |
| Dec 31, 2016 | 5.91 Mn |
| Sep 30, 2016 | 5.00 Mn |
| Jun 30, 2016 | 3.13 Mn |
| Mar 31, 2016 | 6.00 Mn |
| Dec 31, 2015 | 5.08 Mn |
| Sep 30, 2015 | 4.88 Mn |
| Jun 30, 2015 | 6.00 Mn |